NCT05549752 - Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

January 30, 2026

Conditions

Atrial Fibrillation ParoxysmalCoronary Artery Disease Without Residual Ischemia

Interventions

DRUG

Flecainide Injectable Solution

Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.

DRUG

Amiodarone Injectable Solution

Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.

Trial Locations (3)

RECRUITING

First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens

RECRUITING

Konstantopoulio General Hospital, Athens

RECRUITING

KAT General Hospital, Athens